CD79B in myelodysplastic syndromes and acute myeloid leukemia: an integrative computational and in vitro study
These exploratory data suggest that CD79B downregulation is a recurrent feature of MDS and AML and that CD79B may influence leukemic cell behavior and immune microenvironmental signals. The findings generate hypotheses for future mechanistic studies and evaluation of CD79B as a potential biomarker in myeloid malignancies.
Authors
- Xiangjing Kong (ORCID: https://orcid.org/0000-0003-2864-9103)
- Y Eugene Chen
- Xiaoya Lu (ORCID: https://orcid.org/0000-0003-2365-0615)
- Rui Luo
- Bo Liang
- Shengjuan Zhang
- Yongfu Wei
Institutions
- Guangxi Medical University (CN)
- Wuhan Science and Technology Bureau (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- The Second Nanning People's Hospital (CN)
- Fourth Affiliated Hospital of Guangxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-16
- DOI
- https://doi.org/10.3389/fmed.2025.1650035
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Guangxi Province
- Guangxi Medical University